The largest cluster includes therapy, radioimmunotherapy, medullary-thyroid carcinoma, non hodgkins-lymphoma, monoclonal antibody, antibody, bispecific antibody, monoclonal antibodies, positron-emission-tomography, diagnosis, carcinoembryonic antigen, dosimetry, medullary-thyroid cancer, radiotherapy, bivalent hapten, metastases, thyroid cancer, trial, phase-i trial, radioiodine therapy, receptor radionuclide therapy. This evidence concerns the gene CEACAM5 and thyroid gland carcinoma.